Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Oncogene|March 15, 2024
TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancerVinod Kumar, Zachary A Yochum, Princey Devadassan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2017
TMEM16A/ANO1 Inhibits Apoptosis Via Downregulation of Bim ExpressionNeal R Godse, Nayel Khan, Zachary A Yochum, et al.
Molecular Cancer Research : MCR|February 1, 2013
Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancerTimothy F Burns, Irina Dobromilskaya, Sara C Murphy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 9, 2021
A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLCChristine L Hann, Timothy F Burns, Afshin Dowlati, et al.
JCI Insight|December 22, 2020
Syngeneic tobacco carcinogen-induced mouse lung adenocarcinoma model exhibits PD-L1 expression and high tumor mutational burdenLaura P Stabile, Vinod Kumar, Autumn Gaither-Davis, et al.
The Journal of Biological Chemistry|December 17, 2017
Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescenceDaniela Volonte, Avani R Vyas, Chen Chen, et al.
The Oncologist|May 22, 2022
Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain MetastasesRichard S P Huang, Lukas Harries, Brennan Decker, et al.
Advanced Functional Materials|June 2, 2025
Advanced hierarchical computational modeling-based rational development of platinum (II) nanocomplex to improve lung cancer therapyHaozhe Huang, Beihong Ji, Yixian Huang, et al.
Cancer Cell|December 21, 2004
Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growthPeiwen Fei, Wenge Wang, Seok-hyun Kim, et al.
Expert Opinion on Investigational Drugs|June 3, 2022
A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancerByoung Chul Cho, Sarah B Goldberg, Dong-Wan Kim, et al.
Pageof 7